Deal focus: Antengene targets unmet cancer problems
Chinese drug developer Antengene wins backing from the likes of Boyu Capital and FountainVest Partners for a pipeline of treatments that address the country's growing cancer problem
Despite being the world’s second-largest pharmaceutical market, China isn’t known for its prowess in drug innovation. The country has some of the highest incidence rates for cancer, diabetes and liver...
More on Greater China
Latest News
Deal focus: Reworld turns gamers into creators
China's Reworld has a technology that lowers barriers to entry in online game design, allowing anyone to become a creator. Joy Capital is backing the company to take user-generated content to another level
PE-backed Chinese pop toy retailer pursues Hong Kong IPO
Pop Mart International Group, China’s largest fashion toy retailer, has filed for a Hong Kong IPO. Sequoia Capital China, Loyal Valley Capital and Huaxing Growth Fund are its three largest institutional backers.
Singapore fintech launches SME exchange in Cambodia
PLMP Venture Capital (PLMP VC), an investor affiliated with a Singaporean financial technology firm, has launched a local exchange for small and medium-sized enterprises (SMEs) in Cambodia.
India’s Iron Pillar sells GP stake to US investor
Indian venture capital player Iron Pillar Capital Management has brought in US-headquartered real estate investment firm Nitya Capital as a strategic investor.